'Ufh enoxaparin' presentation slideshows

Baseline Characteristics

371 views • 24 slides

796 views • 20 slides

Harvey D. White on behalf of the ACUITY investigators

Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation ACS Managed with an Invasive Strategy: Results from the Randomized ACUITY Trial. Harvey D. White on behalf of the ACUITY investigators.

315 views • 18 slides

Gregg W. Stone MD for the ACUITY Investigators

A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Gregg W. Stone MD for the ACUITY Investigators. Medical management. UFH/Enox + GP IIb/IIIa (n=4,603). PCI. Bivalirudin + GP IIb/IIIa (n=4,604).

249 views • 12 slides